<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">70715</article-id><article-id pub-id-type="doi">10.7554/eLife.70715</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Elevated FBXO45 promotes liver tumorigenesis through enhancing IGF2BP1 ubiquitination and subsequent PLK1 upregulation</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-244059"><name><surname>Lin</surname><given-names>Xiao-Tong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-244060"><name><surname>Yu</surname><given-names>Hong-Qiang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-244061"><name><surname>Fang</surname><given-names>Lei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-244062"><name><surname>Tan</surname><given-names>Ye</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-244063"><name><surname>Liu</surname><given-names>Ze-Yu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-244064"><name><surname>Wu</surname><given-names>Di</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258030"><name><surname>Zhang</surname><given-names>Jie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258031"><name><surname>Xiong</surname><given-names>Hao-Jun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-239991"><name><surname>Xie</surname><given-names>Chuan-Ming</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4362-6612</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution>Third Military Medical University (Army Medical University) Southwest Hospital</institution>, <addr-line><named-content content-type="city">Chongqing</named-content></addr-line>, <country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-244870"><name><surname>Werner</surname><given-names>Haim</given-names></name><role>Reviewing editor</role><aff><institution>Sackler School of Medicine, Tel Aviv University</institution>, <country>Israel</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>cmxie@tmmu.edu.cn</email> (CX);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>15</day><month>11</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e70715</elocation-id><history><date date-type="received"><day>26</day><month>05</month><year>2021</year></date><date date-type="accepted"><day>14</day><month>11</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Lin et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Lin et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-70715-v1.pdf"/><abstract><p>Dysregulation of tumor-relevant proteins may contribute to human hepatocellular carcinoma (HCC) tumorigenesis. FBXO45 is an E3 ubiquitin ligase that is frequently elevated expression in human HCC. However, it remains unknown whether FBXO45 is associated with hepatocarcinogenesis and how to treat HCC patients with high FBXO45 expression. Here, IHC and qPCR analysis revealed that FBXO45 protein and mRNA were highly expressed in 54.3% (57 of 105) and 52.2% (132 of 253) of the HCC tissue samples, respectively. Highly expressed FBXO45 promoted liver tumorigenesis in transgenic mice. Mechanistically, FBXO45 promoted IGF2BP1 ubiquitination at the Lys190 and Lys450 sites and subsequent activation, leading to the upregulation of PLK1 expression and the induction of cell proliferation and liver tumorigenesis <italic>in vitro </italic>and <italic>in vivo</italic>. PLK1 inhibition or IGF2BP1 knockdown significantly blocked FBXO45-driven liver tumorigenesis in FBXO45 transgenic mice, primary cells and HCCs. Furthermore, IHC analysis on HCC tissue samples revealed a positive association between the hyperexpression of FBXO45 and PLK1/IGF2BP1, and both had positive relationship with poor survival in HCC patients. Thus, FBXO45 plays an important role in promoting liver tumorigenesis through IGF2BP1 ubiquitination and activation, and subsequent PLK1 upregulation, suggesting a new strategy for treating HCC by targeting FBXO45/IGF2BP1/PLK1 axis.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>Third Military Medical University</institution></institution-wrap></funding-source><award-id>4174C6</award-id><principal-award-recipient><name><surname>Xie</surname><given-names>Chuan-Ming</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>32071294</award-id><principal-award-recipient><name><surname>Xie</surname><given-names>Chuan-Ming</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Army Medical University and complied with all relevant ethical regulations.(AMUWEC2020936).</p></fn><fn fn-type="other"><p>Human subjects: All human subjects were approved by the Ethics Committee of Southwest Hospital, and all of the patients provided informed consent.  Certificate NO. KY2020127.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures and Figure supplements contain images of gels or blots. Source data files have been provided for the original files of the gels or blots,named as&quot;Source data 1（blot images）&quot;. Source data files have been provided for the clinical and pathological data for HCC patients, namedas&quot;Figure 1-source data 1&quot;. Source data files have been provided for interacted proteins or ubiquitinated proteins, namedas&quot;Supplementary file 4. FBXO45-interacting proteins identified by Co IP-MS&quot;.</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab><collab>Weinstein JN</collab><collab>Collisson EA</collab><collab>Mills GB</collab><collab>Shaw KR</collab><collab>Ozenberger BA</collab><collab>Ellrott K</collab><collab>Shmulevich I</collab><collab>Sander C</collab><collab>Stuart JM</collab></person-group><year iso-8601-date="2013">2013</year><source>The Cancer Genome Atlas Pan-Cancer Analysis Project</source><ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/projects/TCGA-LIHC">https://portal.gdc.cancer.gov/projects/TCGA-LIHC</ext-link><comment>GDC Data Portal, doi:10.1038/ng.2764</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Wurmbach E</collab><collab>Chen YB</collab><collab>Khitrov G</collab><collab>Zhang W</collab><collab>Roayaie S</collab><collab>Schwartz M.</collab></person-group><year iso-8601-date="2007">2007</year><source>Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/download/?acc=GSE6764">https://www.ncbi.nlm.nih.gov/geo/download/?acc=GSE6764</ext-link><comment>NCBI Gene Expression Omnibus, GSE6764</comment></element-citation><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Chen X</collab><collab>Cheung ST</collab><collab>So S</collab><collab>Fan ST</collab><collab>Barry C</collab><collab>Higgins J.</collab></person-group><year iso-8601-date="2002">2002</year><source>Gene expression patterns in human liver cancers</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/download/?acc=GSE3500">https://www.ncbi.nlm.nih.gov/geo/download/?acc=GSE3500</ext-link><comment>NCBI Gene Expression Omnibus, GSE3500</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-70715-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>